Grace Therapeutics (GRCE) Competitors $2.91 -0.01 (-0.34%) As of 11:25 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. BDTX, ACOG, VIGL, NMRA, PROC, RAPT, BHST, CTNM, SGMT, and ALTSShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Black Diamond Therapeutics (BDTX), Alpha Cognition (ACOG), Vigil Neuroscience (VIGL), Neumora Therapeutics (NMRA), Procaps Group (PROC), RAPT Therapeutics (RAPT), BioHarvest Sciences (BHST), Contineum Therapeutics (CTNM), Sagimet Biosciences (SGMT), and Janone (ALTS). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Black Diamond Therapeutics Alpha Cognition Vigil Neuroscience Neumora Therapeutics Procaps Group RAPT Therapeutics BioHarvest Sciences Contineum Therapeutics Sagimet Biosciences Janone Black Diamond Therapeutics (NASDAQ:BDTX) and Grace Therapeutics (NASDAQ:GRCE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Which has better earnings and valuation, BDTX or GRCE? Grace Therapeutics has lower revenue, but higher earnings than Black Diamond Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBlack Diamond Therapeutics$70M1.66-$82.44M$0.0634.08Grace TherapeuticsN/AN/A-$12.85M-$1.16-2.51 Is BDTX or GRCE more profitable? Grace Therapeutics' return on equity of -20.10% beat Black Diamond Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Black Diamond TherapeuticsN/A -68.08% -49.65% Grace Therapeutics N/A -20.10%-17.10% Do insiders & institutionals believe in BDTX or GRCE? 95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 6.1% of Grace Therapeutics shares are owned by institutional investors. 8.9% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 13.5% of Grace Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate BDTX or GRCE? Black Diamond Therapeutics presently has a consensus price target of $14.60, indicating a potential upside of 613.94%. Grace Therapeutics has a consensus price target of $12.00, indicating a potential upside of 312.37%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Black Diamond Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor BDTX or GRCE? In the previous week, Black Diamond Therapeutics had 10 more articles in the media than Grace Therapeutics. MarketBeat recorded 10 mentions for Black Diamond Therapeutics and 0 mentions for Grace Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.35 beat Grace Therapeutics' score of 0.00 indicating that Black Diamond Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Black Diamond Therapeutics Positive Grace Therapeutics Neutral Which has more volatility and risk, BDTX or GRCE? Black Diamond Therapeutics has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Grace Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Does the MarketBeat Community believe in BDTX or GRCE? Black Diamond Therapeutics received 54 more outperform votes than Grace Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Grace Therapeutics an outperform vote while only 71.79% of users gave Black Diamond Therapeutics an outperform vote. CompanyUnderperformOutperformBlack Diamond TherapeuticsOutperform Votes5671.79% Underperform Votes2228.21% Grace TherapeuticsOutperform Votes2100.00% Underperform VotesNo Votes SummaryBlack Diamond Therapeutics beats Grace Therapeutics on 10 of the 15 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$29.51M$6.45B$5.31B$8.42BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.519.0426.7819.69Price / SalesN/A253.23386.97118.34Price / CashN/A65.8538.2534.62Price / Book0.576.406.744.50Net Income-$12.85M$143.98M$3.23B$248.32M7 Day Performance7.38%1.90%1.49%-0.03%1 Month Performance27.07%4.01%11.47%12.72%1 Year PerformanceN/A-3.00%16.57%7.38% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics1.8472 of 5 stars$2.91-0.3%$12.00+312.4%N/A$29.51MN/A-2.51N/AGap UpBDTXBlack Diamond Therapeutics3.1771 of 5 stars$1.93+2.1%$14.60+656.5%-59.2%$109.39MN/A-1.4590News CoveragePositive NewsAnalyst UpgradeGap DownACOGAlpha Cognition1.6715 of 5 stars$6.81-0.7%$20.00+193.7%N/A$109.10MN/A-2.66N/AEarnings ReportVIGLVigil Neuroscience3.2166 of 5 stars$2.32-2.1%$16.25+600.4%-34.0%$108.28MN/A-1.1340Trending NewsAnalyst ForecastGap UpNMRANeumora Therapeutics3.0124 of 5 stars$0.67+8.2%$9.29+1,294.7%-92.0%$107.69MN/A-0.36108PROCProcaps GroupN/A$0.95-40.3%N/A-67.6%$107.18M$409.92M0.004,900Gap DownHigh Trading VolumeRAPTRAPT Therapeutics4.3902 of 5 stars$0.81+7.8%$4.00+394.5%-80.7%$107.01M$1.53M-0.2980Positive NewsAnalyst ForecastBHSTBioHarvest SciencesN/A$6.43-2.6%$13.67+112.5%N/A$105.61M$25.19M-5.15N/ANews CoverageEarnings ReportUpcoming EarningsAnalyst RevisionGap UpCTNMContineum Therapeutics2.1988 of 5 stars$3.94+2.6%$23.75+502.8%-75.9%$101.94M$50M-0.8031Analyst ForecastSGMTSagimet Biosciences1.586 of 5 stars$3.31+6.8%$22.40+576.7%-32.8%$101.53M$2M-1.888ALTSJanoneN/A$6.25+1.3%N/AN/A$100.49M$12.53M0.00170News Coverage Related Companies and Tools Related Companies Black Diamond Therapeutics Alternatives Alpha Cognition Alternatives Vigil Neuroscience Alternatives Neumora Therapeutics Alternatives Procaps Group Alternatives RAPT Therapeutics Alternatives BioHarvest Sciences Alternatives Contineum Therapeutics Alternatives Sagimet Biosciences Alternatives Janone Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRCE Stock Free GRCE Stock Alerts